Survival analysis of the HER2+ breast cancer patients showed that the survival time of patients with high expression of CDK12 was significantly lower than that of patients with low expression, with the difference being statistically significant (P = 0.0074) (Fig. 4F). The gene discussed is CDK12; the disease is breast carcinoma.